Melatonin in bacterial and viral infections with focus on sepsis: A review

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 1, 2012, Pages 30-39

  Srinivasan, Venkataramanujam ^a   Mohamed, Mahaneem ^b   Kato, Hisanori ^c  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti inflammatory; Antimicrobial; Melatonin; Sepsis

Indexed keywords

IRON; ISONIAZID; MELATONIN; MELATONIN RECEPTOR; MYELOPEROXIDASE; PLACEBO;

ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ASPHYXIA; BACTERIAL INFECTION; BIOSYNTHESIS; CHLAMYDIASIS; CRITICALLY ILL PATIENT; DRUG METABOLISM; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; MULTIPLE ORGAN FAILURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATENT; PINEAL BODY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SEPTIC SHOCK; TUBERCULOSIS; VENEZUELAN EQUINE ENCEPHALITIS; VIRUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; HUMANS; LEGISLATION, DRUG; MELATONIN; PATENTS AS TOPIC; SEPSIS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84856559047     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412799015317     Document Type: Article

References (110)

1. Srinivasan V, Spence DW, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: Its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15: 93-101.
2. Baysallar M, Kilic A, Aydogan H, Cilli F, Doganci L. Linezolid and quinupristin resistence in vancomycin-resistent enterococci and methicillin -resistent Staphylococcus aureus prior to clinical use in Turkey. Int J Antimicrob Agents 2004; 23: 510-2.
3. Srinivasan V. The pineal gland: Its physiological and pharmacological role. Ind J Physiol Pharmacol 1989; 33: 263-72.
4. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin. Nature's most versatile signal? FEBJ 2006; 273: 2813-38.
5. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
6. Ben-Nathan D, Maestroni GJ, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol 1995; 140: 223-30.
7. Ben-Nathan D, Maestroni GJM, Conti A. The protective effect of melatonin in viral and bacterial infections. In G.J.M Maestroni, A Conti and RJ Reiter (eds) Therapeutic potential of melatonin. Basel: Karger 1997; 71-80.
8. Wiid I, Hoal-van Helden E, Hon D, Lombard C, van Helder P. Potentiation of isoniazid activity against Myobacterium tuberculosis by melatonin. Antimicrob Agents Chemother 1999; 43: 975-7.
9. Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, et al. Early indicators of chronic lung disease in infant with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 2005; 39: 287-93.
10. Escames G, Lopez LC, Ortiz F, Ros E, Acuna-Castroviejo D. Agedependent lipopolysaccharide-induced iNOS expression and multiorgan failure in rats: Effects of melatonin treatment. Expt Gerontol 2006; 41: 1165-73.
11. Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143: 84-90.
12. Arendt J. Melatonin and the pineal gland: Influence on mammalian seasonal and circadian physiology. Rev Reprod 1988; 3: 12-22.
13. Lane EA, Moss HB. Pharmacokinetics of melatonin in man; first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-6.
14. Di WL, Djahanbakhch O, Kadva A, Street C, Silman R. The pineal and extrapineal origins of 5-sulphatoxy N-acetyl-serotonin in humans. J Pineal Res 1999; 26: 221-6.
15. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. N Eng J Med 2000; 336: 1028-9.
16. Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 IA2 activity in vivo: A pilot study. Clin Pharmacol Ther 2001; 70: 10-6.
17. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-85.
18. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8.
19. Godson C, Reppert SM. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinol 1997; 138: 397-404.
20. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Identification of the melatonin binding site MT3 as the quinone reductase 2. J Biol Chem 2001; 275: 31311-7.
21. Ekmekcioglu C. Melatonin receptors in humans. Biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-101.
22. Becker-Andre M, Wiesenberg I, Schaeren-Wiemer N, Andre E, Missbach M, Saurat JH, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994; 269: 28531-4.
23. Giguere V. Orphan nuclear receptors: From gene to function. Endocrine Rev 1999; 20: 689-725.
24. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJM, Zisapel N, et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-53.
25. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin-A pleiotropic orchestring molecule. Prog Neurobiol 2011; 93: 350-84.
26. Tan DX, Chen LD, Poeggeler B. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1: 57-60.
27. Tan DX, Poeggeler B, Reiter RJ. The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Letter 1993; 70: 65-71.
28. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. Melatonin: A peroxyl radical scavenger more effective than vitamin E. Life Sciences 1994; 55: L271-6.
29. Sewerynek E, Melchiorri D, Ortiz GG, Poeggeler B, Reiter RJ. Melatonin reduces H2O2 induced lipid peroxidation in homogenates of different rat brain regions. J Pineal Res 1995; 19: 51-6.
30. Sewerynek E, Melchiorri D, Reiter RJ, Ortiz GG, Lewinski A. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 1995; 293: 327-34.
31. Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabo C. Melatonin is a scavenger of peroxynitrite. Life Sciences 1997; 60: 169-74.
32. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochemistry Biophys 2001; 34: 237-54.
33. Tan DX, Reiter RJ, Manchester LC, Yan MT, ElSwai M, Sainz RM, Mayo JC, Kohen R,Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-197.
34. Rosen J, Than NN, Koch D, Poeggeler B, Laatsch H, Hardeland R. Interactions of melatonin and its metabolites with ABTS cation radical: Extension of radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006; 41:374-81.
35. Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neurohormone melatonin antioxidative protection and formation of bioactive substances. J Trauma 1993; 17: 347-357.
36. Reiter RJ. Interactions of the pineal hormone melatonin with oxygen centered free radicals: A brief review. Braz J Med Biol Res 1993; 26: 1141-55.
37. Morrey KM, McLachlan JA, Serkin CD, Bakouche O. activation of monocytes by the pineal hormone melatonin. J immunol 1994; 153: 2671-80.
38. Cristafanon S, Uguccioni F, Cerella C, Radogna F, Dicato M, Ghibelli L, et al. Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-κB activation. Ann NY Acad Sci 2009; 1171: 472-8.
39. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H. The role of IFN-gamma in the outcome of chlamydial infection. Curr Opin Immunol 2001; 14: 444-51.
40. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthma, bronchitis and adult-onset asthma. JAMA 1991; 266: 225-30.
41. Schachter J. Chlamydial infections (first of three parts). New Engl J Med 1978; 298: 428-35.
42. Kalman SMW, Marathe R, Lammel C, Fan J, Hyman RW, Olinger L, et al. Comparitive genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet 1999; 21: 385-9.
43. Pantoja LG, Miller RD, Ramirez JA,Molestina RE, Summersgill JT. Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2,3-dioxygenase activity. Infect Immune 2000; 68: 6478-81.
44. Xie GBC, Bonner CA, Jensen RA. Dynamic diversity of the of the tryptophan pathway in chlamydiae: Reductive evolution and a novel operon for tryptophan metabolism recapture. Genome Biol 2002; 51: 1-17.
45. Mehta SJ, Miller RD, Ramirez JA, Summersgill JT. Inhibition of Chlamydia pneumonia replication in HEp-2 cells by interferongamma: Role of tryptophan catabolism. J Infect Dis 1998; 177: 1326-31.
46. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003; 81: 247-65.
47. Valero N, Bonilla E, Pons H, Chacin-Bonilla L, Anez F, Espina LM, et al. Melatonin induces changes to serum cytokines in mice infected with the Venezuelan equine encephalomyelitis virus. Trans R Soc Trop Med Hyg 2002; 96: 348-51.
48. Rahman MA, Azuma Y, Fukunaga H, Murakami T, Sugi K, Fukushi K, et al. Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite Chlamydia. J Antimicrobial Chemotherapy 2005; 56: 861-8.
49. Ward ME, Salari H. Control mechanisms governing the infectivity of Chlamydia trachomatis for hela cells: Modulation by cyclic nucleotides, prostaglandins and calcium. J Gen Microbiol 1982; 128: 639-50.
50. Tekbas OF, Ogur R, Korkmaz A, Killic A, Reiter RJ. Melatonin as an antibiotic: New insights into the actions of this ubiquitous molecule. J Pineal Res 2008; 44: 222-26.
51. Ward CG, Bullen JJ, Rogers HJ. Iron and infection: new developments and their implications. J Trauma 1996; 41: 356-364.
52. Nauseef WM, Malech HL. Analysis of the peptide subunits of human neutrophil myeloperoxidase. Blood 1986; 67: 1504-07.
53. Klebanoff SJ, Waltersdorph AM, Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 1984; 105: 399-403.
54. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radical Biol Med 2000; 28: 1717-25.
55. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1032-11.
56. Xu W, Zheng S, Dweik RA, Erzurum SC. Role of epithelial nitric oxide in airway viral infections. Free Radical Biol Med 2006; 41: 19-28.
57. Pattison DI, Davies MJ. Reactions of myeloperoxidase -derived oxidants with biological substrates: Gaining chemical insight into human inflammatory diseases. Curr Med Chem 2006; 13: 3271-90.
58. Glijasevic S, Abdulhamid I, Husam M, Abu-Sood. Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry 2008; 47: 2668-77.
59. Bowen GS, Calisher CH. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. J Clin Microbiol 1976; 4: 22-7.
60. Weaver SC, Salas R, Rico-Hesse R, Ludwig GV, Oberste MS, Boshell J, et al. Reemergence of epidemic Venezuelian equine encephalomyelitis virus in South America. Lancet 1996; 358: 436-40.
61. Bonilla E, Valero N, Pons H, Chacin-Bonilla L. Melatonin protects mice infected with Venezulean equine encephalomyelitis virus. Cell Mol Life Sci 1997; 53: 430-34.
62. Bonilla E, Rodon C, Valero N, Pons H, Chacin-Bonilla L, Garcia Tamayo J, et al. Melatonin prolongs survival of immunodepressed mice infected with the Venezuelan equine encephalomyelitis virus. Trans R Soc Trop Med Hyg 2001; 95: 207-10.
63. Finocchiaro LM, Artz ES, Fernandez S, Crisculo M, Finkielman S, Nahmod VE. Serotonin and melatonin synthesis in peripheral blood mononuclear cells stimulation by interferon -gamma as part of the immunomodulatory pathway. J Interferon Res 1988; 8: 705-16.
64. Valero N, Bonilla E, Pons H, Chacin-Bonilla L, Anez F, Espina LM, et al. Melatonin induces changes to serum cytokines in mice infected with the venezulan equine encephalomyelitis virus. Trans R Soc Trop Med Hyg 2002; 96: 1-4.
65. Bonilla E, Valero N, Chacin-Bonilla L, Pons H, Larreal Y, Medina- Leendert S, et al. Melatonin increases interleukin-1β and decreases tumor necrosis factor alpha in the brain of mice infected with the Venezuelean equine encephalomyelitis virus. Neurochem Res 2003; 28: 687-92.
66. Bonilla E, Valero N, Chacin-Bonilla L, Medina-Leendertz S. Melatonin and viral infections. J Pineal Res 2004; 36: 73-79.
67. Baker CC, Huynh T. Sepsis in the critically ill patients. Curr Probl Surg 1995; 32: 1013-92.
68. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-91.
69. Annane D, Bellissant E, Cavallion JM. Septic shock. Lancet 2005; 365: 63-78.
70. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33: 1538-48.
71. Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect 1995; 30: 201-6.
72. Victor VM, Rocha M, De La Fuente M. Immune cells: Free radicals and antioxidants in sepsis. Int Immunopathol 2004; 4: 327-47.
73. Tsiotoo AG, Sakorafas GH, Anagnostopoolos G, Bramis J. Septic shock: Current pathogenetic concepts from a clinical perspective. Med Sci Monit 2005; 11: RA76-RA85.
74. Pinsky MR. Sepsis, a pro and anti-inflammatory disequilibrium. Contrib Nephrol 2001; 132: 354-66.
75. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines. Adv Immunol 1994; 55: 97-179.
76. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor ά and interleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock. J Exp Med 1996; 183: 949-58.
77. Carreras MC, Franco MC, Peralta JG, Poderoso JJ. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 2004; 25: 125-39.
78. Boveris DJ, Alvarez S, Navarro A. The role of mitochondrial nitric oxide synthase in inflammation and septic shock. Free radical Biol Med 2002; 33: 1186-93.
79. Escames G, Leon J, Macias M, Khaldy H, Acuna-Castroviejo. Melatonin counteracts lipopolysacchardide-induced expression and activity of mitochondrial nitric-oxide synthase in rats. FEBS J 2003; 17: 932-34.
80. Annane D, Bellisant E, Bollaert P, Brigel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis. Br Med J 2004; 329: 480.
81. Wu CC, Chiao CW, Hsiao G, Chen A, Yen MH. Melatonin prevents endotoxin-induced circulatory failue in rats. J Pineal Res 2001; 30: 147-56.
82. Carrillo-Vico A, Lardone PJ, Naji L, Fernandez-Santos JM, Martin- Lacave I, Guerrero JM, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: Regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39: 400-8.
83. Wu J-Y, Tsou MY, Chen TH, Chen SJ, Tsao CM, Wu CC. Therapeutic effects of melatonin on peritonitis-induced septic shock with multiple organ dysfunction syndrome in rats. J Pineal Res 2008; 45: 106-16.
84. Adams JM, Hauser CJ, Adams CA Jr, Xu DZ, Livingston DH, Deitch EA. Entry of gut lymph into the circulation primes rat neutrophil respiratory burst in hemorrhagic shock. Crit Care Med 2001; 29: 2194-8.
85. Heller AR, Groth G, Heller SC, Breitkreutz R, Nebe T, Quintel M, et al. N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. Crit Care Med 2001; 29: 272-6.
86. De Filipps D, Iuvone T, Esposito G, Sterdo L, Arnold GH, Paul AP, et al. Melatonin reverses lipopolysaccharide-induced gastrointestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res 2008; 44: 45-51.
87. De Winter BY, van Nassaow L, de Man JG, De Jonge F, Bredenoord AJ, Seerden TC, et al. Role of the oxidative stress in the pathogenesis of septic ileus in mice. Neurogastroenterol Motil 2005; 17: 251-61.
88. Hussain SNA. Respiratory muscle dysfunction in sepsis. Mol Cell Biochem 1998; 179: 125-34.
89. Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci 2005; 26: 190-5.
90. Poderoso JJ, Carreras MC, Lisdero C. Nitric oxide inhibits electron transfer and increases O2 - radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 1996; 308: 89-95.
91. Martin M, Macias M, Escames G, Reiterr RJ, Agapito MT, Ortiz GG, et al. Melatonin induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28: 242-8.
92. Martin M, Macias M, Escames G, Leon J, Acuna-Castroviejo D. Melatonin but not vitamin C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000; 14: 1677-9.
93. Karbownik M, Tan D, Manchester LC, Reiter RJ. Renal toxicity of the carcinogen delta-aminolevulinic acid: Anti-oxidant effects of melatonin. Cancer Lett 2000; 161: 1-7.
94. Park JW, Youn YC, Kwon OS, Jang YY, Han ES, Lee CS. Protective effect of serotonin on 6-hydroxydopamione and dopamine induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem Int 2002; 40, 223-33.
95. Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9.
96. Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin septic shock. J Critical Care 2010; 25: 656e1-e6.
97. Srinivasan V, Spence DW, Pandi-Perumal SR, Brown GM, Cardinali DP. Melatonin in mitochondrial dysfunction and related disorders. Int J Alzheimer's disease 2011; 2011:326320.
98. Kirton OC, Civetta JM. Ischemia-reperfusion injury in the critically ill: A progenitor of multiple organ failure. New Horizons 1999; 7: 87-95.
99. Mundigler G, Delle-Karth G, Koreny M, Zehetgruber M, Steindl- Munda P, Marktl W, et al. Impaired circadian rrhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 2002; 30: 536-40.
100. Bourne RS, Mills GH. Melatonin: Possible implications for the postoperative and critically ill patient. Intensive Care Med 2006; 32: 371-79.
101. Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care paients. Acta Anaesthesiol Scand 2004; 48: 679-84.
102. Frisk U, Olsson J, Nylen P, Hahn RG. Low melatonin excretion during mechanical ventilation in the intensive care unit. Clin Sci 2004; 107: 47-53.
103. Perras B, Kurowski V, Dodt C. Nocturnal melatonin concentration is correlated with illness severity in patients with septic disease. Intensive Care Med 2006; 32, 624-5.
104. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi S, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50: 756-60.
105. Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, et al. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 2004; 36: 250-5.
106. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the new born in the pre-and postnatal period and the clinical utility of melatonin. J Pineal Res 2009; 46: 128-39.
107. Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: Encouraging results from a small randomized controlled trial. Crit Care 2008; 12: R52
108. Monnonen, I., Kelo, E. Method for treatment of cancers or inflammatory diseases. US20100143324 (2010).
109. Sileri, P., Sica, G.S., Gentieleschi, P., Venza, M., Benavoli, D., Jarzembowski, T., Manzalli, A., Gaspari, A.L. Melatonin reduces bacterial translocation after intestinal ischemia reperfusion injury. EP1744746 (2005).
110. Schneider, H. Use of melatonin in preventing postoperative complications. EP2316451 (2011).